Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes

Claudia Cangemi, Vibe Skov, Michael Kjaer Poulsen, Jonas Funder, Waleed O. Twal, Mari Anne Gall, Vibeke Hjortdal, Marie Louise Jespersen, Torben A. Kruse, Jan Aagard, Hans Henrik Parving, Steen Knudsen, Poul Flemming Høilund-Carlsen, Peter Rossing, Jan Erik Henriksen, William Scott Argraves, Lars Melholt Rasmussen*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    BACKGROUND: Extracellular matrix alterations are important elements in the arterial changes seen in diabetes, being associated with increased vascular stiffness and the development of cardiovascular diseases. However, no biomarkers for diabetes-related arterial changes have been defined. METHODS: Mammary artery specimens from 17 men with type 2 diabetes and 18 nondiabetic individuals were used for microarray expression profiling, quantitative real-time PCR, immunoassay, and immunohistochemical analyses. A derived candidate marker, fibulin-1, which is an elastin-associated matrix molecule, was measured immunochemically in plasma from (a) 70 patients scheduled for vascular surgery, (b) 305 patients with type 2 diabetes examined with carotid ultrasonography and echocardiography, and (c) 308 patients with type 2 diabetes, followed for 15 years. RESULTS: The most upregulated transcript in nonatherosclerotic arterial tissue from patients with type 2 diabetes encoded the extracellular matrix protein, fibulin-1. Higher concentrations of fibulin-1-protein were present in artery extracts from patients with diabetes than extracts from individuals without diabetes, and increased fibulin-1 immunostaining was apparent around the external elastic lamina of diabetic arteries. Patients with diabetes displayed increased plasma concentrations of fibulin-1 (P = 0.006). Plasma fibulin-1 concentrations correlated with hemoglobin A 1c (P < 0.001), arterial stiffness indices including pulse pressure (P < 0.001), and carotid compliance (P = 0.004), as well as plasma N-terminal pro-B-type natriuretic peptide concentrations (P < 0.001) and were predictive of 15-year mortality (P = 0.013). CONCLUSIONS: Fibulin-1 accumulates in the arterial wall and in plasma of patients with type 2 diabetes, and appears to be a factor associated with arterial extracellular matrix changes in type 2 diabetes.

    Sider (fra-til)1556-1565
    Antal sider10
    TidsskriftClinical Chemistry
    Udgave nummer11
    StatusUdgivet - 1 nov. 2011


    Udforsk hvilke forskningsemner 'Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes' indeholder.